Jeff Lerch of CB Richard Ellis, who represented HemoCue in the planning, selection, and negotiations for the site, says the company is expected to move into its new facility in December from its current U.S. headquarters in nearby Mission Viejo. The company has leased the freestanding, single-story building for five years at a total consideration of $1.3 million. The concrete tilt-up R&D building, which includes office space as well as labs, was completed in 1999.

HemoCue develops, produces and markets medical diagnostic products for point-of-care testing. The fundamental concept behind the HemoCue products is to perform common blood tests at the point-of-care without sacrificing the accuracy and precision offered by a central clinical lab. The company's customers include blood banks, medical offices, public health care screening programs, hospital emergency rooms, operating rooms, dialysis clinics and outpatient surgery centers.

HemoCue, Inc. is wholly owned by its Swedish parent, HemoCue Holding AB, based in Angelholm, Sweden. The company sells its products in more than 75 countries and is considered a leader in point-of-care blood testing.